Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

385 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Disruption of the EGFR E884-R958 ion pair conserved in the human kinome differentially alters signaling and inhibitor sensitivity.
Tang Z, Jiang S, Du R, Petri ET, El-Telbany A, Chan PS, Kijima T, Dietrich S, Matsui K, Kobayashi M, Sasada S, Okamoto N, Suzuki H, Kawahara K, Iwasaki T, Nakagawa K, Kawase I, Christensen JG, Hirashima T, Halmos B, Salgia R, Boggon TJ, Kern JA, Ma PC. Tang Z, et al. Among authors: hirashima t. Oncogene. 2009 Jan 29;28(4):518-33. doi: 10.1038/onc.2008.411. Epub 2008 Nov 17. Oncogene. 2009. PMID: 19015641 Free PMC article.
Telomerase activity in endoscopically visible lung cancer.
Hirashima T, Yoshitaka O, Nitta T, Sasada S, Kobayashi M, Masuda N, Matsui K, Nakagawa K, Yasumitsu T, Takada Y, Kikui M, Kawase I. Hirashima T, et al. Anticancer Res. 2001 Sep-Oct;21(5):3685-9. Anticancer Res. 2001. PMID: 11848543
CYP2C19 genotype-based phase I studies of a c-Met inhibitor tivantinib in combination with erlotinib, in advanced/metastatic non-small cell lung cancer.
Yamamoto N, Murakami H, Hayashi H, Fujisaka Y, Hirashima T, Takeda K, Satouchi M, Miyoshi K, Akinaga S, Takahashi T, Nakagawa K. Yamamoto N, et al. Among authors: hirashima t. Br J Cancer. 2013 Nov 26;109(11):2803-9. doi: 10.1038/bjc.2013.588. Epub 2013 Oct 29. Br J Cancer. 2013. PMID: 24169346 Free PMC article. Clinical Trial.
A randomized, double-blind, placebo-controlled, phase III trial of erlotinib with or without a c-Met inhibitor tivantinib (ARQ 197) in Asian patients with previously treated stage IIIB/IV nonsquamous nonsmall-cell lung cancer harboring wild-type epidermal growth factor receptor (ATTENTION study).
Yoshioka H, Azuma K, Yamamoto N, Takahashi T, Nishio M, Katakami N, Ahn MJ, Hirashima T, Maemondo M, Kim SW, Kurosaki M, Akinaga S, Park K, Tsai CM, Tamura T, Mitsudomi T, Nakagawa K. Yoshioka H, et al. Among authors: hirashima t. Ann Oncol. 2015 Oct;26(10):2066-72. doi: 10.1093/annonc/mdv288. Epub 2015 Jul 7. Ann Oncol. 2015. PMID: 26153496 Free article. Clinical Trial.
385 results